Clinical Trials Logo

Filter by:
NCT ID: NCT05203809 Recruiting - Lymphoma Clinical Trials

Continuous Temperature Monitoring for tHe Early Recognition of Febrile Neutropenia in Haematological MALignancies

THERMAL
Start date: November 18, 2021
Phase:
Study type: Observational

The THERMAL study is a pilot study to determine feasibility of using two separate continuous skin temperature monitors during intensive treatment for haematological malignancies. It involves participants wearing both the TempTraq and CORE temperature devices for up to 14 days, and then assessing their feasibility and tolerability with quantitative, semiquantitative and qualitative methods.

NCT ID: NCT05197049 Recruiting - Crohn Disease Clinical Trials

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease

GRAVITI
Start date: January 17, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with Crohn's disease.

NCT ID: NCT05183646 Not yet recruiting - FSGS Clinical Trials

A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB

ACTION3
Start date: February 2022
Phase: Phase 3
Study type: Interventional

DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit recruitment of monocytes implicated in the inflammatory chemokine environment of chronic disease. The purpose of this pivotal randomized double-blind study is to investigate the efficacy and safety of DMX-200 120 mg twice daily (BID) compared with placebo over a treatment period of 104 weeks in adult patients with biopsy-proven FSGS who are being treated with an ARB.

NCT ID: NCT05177809 Recruiting - Ataxia Clinical Trials

RFC1 Natural History Study

RFC1-NHS
Start date: December 14, 2021
Phase:
Study type: Observational [Patient Registry]

This international, multi-center, multi-modal and prospective observational study aims to determine the phenotypic spectrum and the natural progression of the RFC1 repeat expansion disease, and to seek and validate digital, imaging, and molecular biomarkers that aid in diagnosis and serve as outcome measures in future clinical trials of this novel, but frequent ataxia with late adult-onset.

NCT ID: NCT05171647 Not yet recruiting - Clinical trials for Non-Hodgkin Lymphoma

A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

SUNMO
Start date: March 31, 2022
Phase: Phase 3
Study type: Interventional

This study will assess the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin (M+P) in participants with relapsed or refractory (R/R) diffuse-large B-cell lymphoma (DLBCL), transformed follicular lymphoma (trFL) and FL Grade 3B (FL3B) in comparison with a commonly used regimen in this participant population, rituximab, gemcitabine and oxaliplatin (R-GemOx).

NCT ID: NCT05154240 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects

Start date: February 24, 2022
Phase: Phase 1
Study type: Interventional

The sponsor is planning to conduct a Phase 1, randomized, double-blind, placebo-controlled, oral single and multiple ascending-doses, parallel group study to evaluate the safety, tolerability and PK of INS018_055 in healthy subjects. The study will be conducted in 1 clinical site in the New Zealand, consisting of 2 parts: Part A (single ascending dose [SAD]) and Part B (multiple ascending dose [MAD]).

NCT ID: NCT05146882 Enrolling by invitation - Clinical trials for Alpha 1-Antitrypsin Deficiency

An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)

Start date: December 2021
Phase: Phase 2
Study type: Interventional

This is a Phase 2, multicenter, open-label extension of Study DCR-A1AT-201, designed to evaluate the long-term safety and further characterize the pharmacodynamics (PD) of belcesiran in adult patients with PiZZ AATLD.

NCT ID: NCT05137119 Not yet recruiting - Clinical trials for Staphylococcus Aureus Bacteremia

Staphylococcus Aureus Network Adaptive Platform Trial

SNAP
Start date: December 1, 2021
Phase: Phase 4
Study type: Interventional

The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).

NCT ID: NCT05133492 Recruiting - Clinical trials for Abdominal Aortic Aneurysm

First In Human Study for Small to Medium-sized Abdominal Aortic Aneurysm (AAA)

AAA
Start date: June 24, 2019
Phase: N/A
Study type: Interventional

This is a first in human study to evaluate the safety and clinical utility of an investigational medical device called the Nectero EAST System to treat Abdominal Aortic Aneurysms or AAA.

NCT ID: NCT05123599 Not yet recruiting - Clinical trials for Hepatitis B, Chronic

A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection

OSPREY
Start date: November 26, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the efficacy of the study intervention based on hepatitis B surface antigen (HBsAg) levels.